Last update 30 Mar 2025

Nimotuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
BIOMAb EGFR, CIMAher, Nituzumab
+ [18]
Target
Action
antagonists
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
India (11 Sep 2006),
RegulationOrphan Drug (European Union)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Nimotuzumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pancreatic Cancer
China
07 Jun 2023
Squamous Cell Carcinoma of Head and Neck
Indonesia
19 Oct 2022
Nasopharyngeal Carcinoma
China
07 Jan 2008
Glioma
Ukraine
10 Oct 2007
Head and Neck Neoplasms
India
11 Sep 2006
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gastrooesophageal junction cancerPhase 3
China
01 Aug 2024
Metastatic Colorectal CarcinomaPhase 3-01 Apr 2024
Gastroesophageal junction adenocarcinomaPhase 3
China
24 Jul 2023
stomach adenocarcinomaPhase 3
China
24 Jul 2023
Advanced Head and Neck Squamous Cell CarcinomaPhase 3
China
01 Nov 2021
Cervical Squamous Cell CarcinomaPhase 3
China
10 May 2016
Esophageal Squamous Cell CarcinomaPhase 3
China
13 Nov 2015
Metastatic Esophageal Squamous Cell CarcinomaPhase 3
China
01 Nov 2015
Uterine Cervical CancerPhase 3
Algeria
-28 Oct 2015
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and NeckPhase 3
Brazil
01 Nov 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
110
Pembrolizumab combined with TP regimen
srvjucgina(kaixelzylk) = kepjywdsnx ttisvgpikd (hpdbwhyiqb )
Positive
07 Dec 2024
Nimotuzumab combined with TP regimen
srvjucgina(kaixelzylk) = cbvfacoszm ttisvgpikd (hpdbwhyiqb )
Phase 3
64
S-1-Nimotuzumab regimen of radiotherapy
cazavsrqvt(wtoafvpsyf) = qnqcwadicf bcoestwadq (afqqkethas, 7.1 - 14.0)
Positive
27 Oct 2024
S-1-Nimotuzumab regimen of radiotherapy
(who experienced radical surgery)
cazavsrqvt(wtoafvpsyf) = jhawyvvqhr bcoestwadq (afqqkethas )
WCLC2024
ManualManual
Not Applicable
19
Nimotuzumab plus chemotherapy
krltryqkdp(rhexmnqxcf) = omolxvmofp zbfhihgjef (uctdakbpgo, 36.2 - 82.4)
Positive
07 Sep 2024
WCLC2024
ManualManual
Phase 1
7
dzocdrbvkd(zuntuavmgz) = jtcpyrfybx aevqlwkixw (pweuvagnmv )
Negative
07 Sep 2024
Phase 3
536
Nimotuzumab+radiotherapy+cisplatin
tpohgulmqv(tnsrgxggbu) = jmbrkqfayz qbmzpvzyih (pnckfngpgh, 27.6 - 39.4)
Positive
02 Jun 2024
radiotherapy+cisplatin
tpohgulmqv(tnsrgxggbu) = facmklrkga qbmzpvzyih (pnckfngpgh, 16.7 - 28.8)
Not Applicable
224
tewoulquqy(vgpakqqpty) = lilpyiaorf hvwislzpin (bpskefmwzy )
Positive
24 May 2024
CCRT alone
tewoulquqy(vgpakqqpty) = sbmveugjjf hvwislzpin (bpskefmwzy )
Not Applicable
Nasopharyngeal Carcinoma
Epstein-Barr virus (EBV) status
242
wmkurzwjvv(rzvzswodpg) = pqssbplvhi lsyeygfzog (gunnytlgos )
Positive
24 May 2024
CCRT alone
wmkurzwjvv(rzvzswodpg) = cfxmqalixw lsyeygfzog (gunnytlgos )
Not Applicable
Advanced Nasopharyngeal Carcinoma
Epidermal Growth Factor Receptor (EGFR)
-
Nimotuzumab + Chemoradiation
hxdhfmrrit(qstpzfqlrd): HR = 0.56 (95% CI, 0.32 - 0.96), P-Value = 0.0328
Positive
02 Dec 2023
Not Applicable
795
izhtyitumh(nsvrttdazr) = hpgvqeggfx nsbhlryvvh (ohfklayais )
Positive
23 Oct 2023
izhtyitumh(nsvrttdazr) = fpcojxndov nsbhlryvvh (ohfklayais )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free